HSP27 inhibitor J2
HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition[1][2].
Product Specifications
CAS Number
2133499-85-9
Product Name Alternative
J2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hsp27-inhibitor-j2.html
Purity
99.70
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
O=C1C=C(C)OC2=C1C(O)=CC(OCC3SC3)=C2
Molecular Formula
C13H12O4S
Molecular Weight
264.30
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human IgG Immunoglobulin (IG266), CF647 conjugate, 0.1mg/mL
TGF-beta (1D11.16.8), CF770 conjugate, 0.1mg/mL
Cytokeratin, LMW (AE-1), CF594 conjugate, 0.1mg/mL
CD50 (ICAM-3) (186-2G9), CF488A conjugate, 0.1mg/mL
